HRP20131120T1 - Farmaceutski pripravak koji sadrži (1s)-1,5-anhidro-1-[5-(4-etoksibenzil)-2-metoksi-4-metilfenil]-1-tio-d-glucitol i metformin, te njegova uporaba za lijeäśenje dijabetesa - Google Patents
Farmaceutski pripravak koji sadrži (1s)-1,5-anhidro-1-[5-(4-etoksibenzil)-2-metoksi-4-metilfenil]-1-tio-d-glucitol i metformin, te njegova uporaba za lijeäśenje dijabetesa Download PDFInfo
- Publication number
- HRP20131120T1 HRP20131120T1 HRP20131120AT HRP20131120T HRP20131120T1 HR P20131120 T1 HRP20131120 T1 HR P20131120T1 HR P20131120A T HRP20131120A T HR P20131120AT HR P20131120 T HRP20131120 T HR P20131120T HR P20131120 T1 HRP20131120 T1 HR P20131120T1
- Authority
- HR
- Croatia
- Prior art keywords
- metformin
- ethoxybenzyl
- glucitol
- anhydro
- thio
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009100210 | 2009-04-16 | ||
| PCT/JP2010/057196 WO2010119990A1 (en) | 2009-04-16 | 2010-04-16 | Pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20131120T1 true HRP20131120T1 (hr) | 2013-12-20 |
Family
ID=42982643
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20131120AT HRP20131120T1 (hr) | 2009-04-16 | 2010-04-16 | Farmaceutski pripravak koji sadrži (1s)-1,5-anhidro-1-[5-(4-etoksibenzil)-2-metoksi-4-metilfenil]-1-tio-d-glucitol i metformin, te njegova uporaba za lijeäśenje dijabetesa |
| HRP20141080AT HRP20141080T1 (hr) | 2009-04-16 | 2014-11-05 | Farmaceutski pripravci s (1s) -1,5-anhidro-1 [5-(4-etoksibenzil)-2-metoksi-4-metilfenil]-1-tio-d-glucitolom i sekretagogom inzulina |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20141080AT HRP20141080T1 (hr) | 2009-04-16 | 2014-11-05 | Farmaceutski pripravci s (1s) -1,5-anhidro-1 [5-(4-etoksibenzil)-2-metoksi-4-metilfenil]-1-tio-d-glucitolom i sekretagogom inzulina |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US20120040898A1 (enExample) |
| EP (3) | EP2419097B1 (enExample) |
| JP (4) | JP5077786B2 (enExample) |
| KR (2) | KR20150046382A (enExample) |
| CN (7) | CN105343871A (enExample) |
| AR (1) | AR076317A1 (enExample) |
| AU (1) | AU2010237748B2 (enExample) |
| BR (1) | BRPI1012539A2 (enExample) |
| CA (1) | CA2755392A1 (enExample) |
| CY (2) | CY1114703T1 (enExample) |
| DK (2) | DK2419097T3 (enExample) |
| ES (2) | ES2523408T3 (enExample) |
| HK (6) | HK1217302A1 (enExample) |
| HR (2) | HRP20131120T1 (enExample) |
| ME (2) | ME02015B (enExample) |
| MX (1) | MX2011010901A (enExample) |
| MY (3) | MY183793A (enExample) |
| NZ (4) | NZ606888A (enExample) |
| PH (3) | PH12015500235A1 (enExample) |
| PL (2) | PL2601949T3 (enExample) |
| PT (2) | PT2419097E (enExample) |
| RS (2) | RS53761B1 (enExample) |
| RU (2) | RU2532330C2 (enExample) |
| SG (6) | SG2014012405A (enExample) |
| SI (2) | SI2419097T1 (enExample) |
| SM (1) | SMT201500015B (enExample) |
| TW (3) | TW201622720A (enExample) |
| UA (2) | UA105216C2 (enExample) |
| WO (1) | WO2010119990A1 (enExample) |
| ZA (1) | ZA201106727B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
| KR20110118668A (ko) | 2009-02-13 | 2011-10-31 | 베링거 인겔하임 인터내셔날 게엠베하 | １형 당뇨병, ２형 당뇨병, 내당능 장애 또는 고혈당증을 치료하기 위한 ｓｇｌｔ２ 억제제 |
| DK2486029T3 (en) | 2009-09-30 | 2015-08-24 | Boehringer Ingelheim Int | Methods of making of glucopyranosyl-substituted benzyl-benzene derivatives. |
| US10610489B2 (en) | 2009-10-02 | 2020-04-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
| US20120283169A1 (en) * | 2010-11-08 | 2012-11-08 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| TR201101809A1 (tr) * | 2010-12-21 | 2012-07-23 | Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ | Vildagliptin ve glimepirid kombinasyonları. |
| US9192617B2 (en) | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| IN2014DN09554A (enExample) | 2012-05-17 | 2015-07-17 | Transtech Pharma Llc | |
| RU2015110979A (ru) * | 2012-08-30 | 2016-10-20 | Тайсо Фармасьютикал Ко., Лтд. | Комбинации ингибиторов sglt 2 и антигипертензивных лекарственных средств |
| HRP20190101T1 (hr) | 2013-04-05 | 2019-03-08 | Boehringer Ingelheim International Gmbh | Terapeutske uporabe empagliflozina |
| US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US20140303097A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CA2812519A1 (en) | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| PL2986304T3 (pl) | 2013-04-18 | 2022-05-02 | Boehringer Ingelheim International Gmbh | Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania |
| TW201513857A (zh) * | 2013-07-05 | 2015-04-16 | Cadila Healthcare Ltd | 協同性組成物 |
| BR112017018329A2 (pt) * | 2015-02-27 | 2018-08-07 | The Asan Foundation | composição para prevenir ou tratar calcificação de válvula, contendo inibidor de dpp-4 |
| CN105963280B (zh) * | 2016-06-30 | 2018-11-06 | 合肥华方医药科技有限公司 | 一种伏格列波糖口腔速溶膜及其制备方法 |
| CA3041169A1 (en) | 2016-10-19 | 2018-04-26 | Boehringer Ingelheim International Gmbh | Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof |
| WO2018087132A1 (en) | 2016-11-10 | 2018-05-17 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US11439689B2 (en) * | 2016-11-14 | 2022-09-13 | Kaohsiung Medical University | Method for detecting whether glucose metabolism is abnormal, and prevention and treatment therefor |
| US20210113561A1 (en) | 2018-04-17 | 2021-04-22 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| KR20190137343A (ko) | 2018-06-01 | 2019-12-11 | 김유찬 | 계량 인덕션 |
| CA3093025A1 (en) | 2018-06-12 | 2019-12-19 | Vtv Therapeutics Llc | Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs |
| JP7425793B2 (ja) | 2018-10-29 | 2024-01-31 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ピリジニルスルホンアミド誘導体、医薬組成物およびそれらの使用 |
| CA3112510A1 (en) | 2018-10-29 | 2020-05-07 | Boehringer Ingelheim International Gmbh | Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof |
| US12391658B2 (en) | 2020-02-18 | 2025-08-19 | Vtv Therapeutics Llc | Sulfoxide and sulfone glucokinase activators and methods of use thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4432757A1 (de) | 1994-09-14 | 1996-03-21 | Boehringer Mannheim Gmbh | Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung |
| JP2003520759A (ja) | 1999-08-31 | 2003-07-08 | アンドルックス ファーマスーティカルズ インコーポレーテッド | 単位核を有する徐放性錠剤 |
| US20030045553A1 (en) * | 2001-04-04 | 2003-03-06 | Bussolari Jacqueline C. | Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators |
| DK1385856T3 (da) * | 2001-04-11 | 2006-05-15 | Bristol Myers Squibb Co | Aminosyrekomplekser af C-aryl-glucosider til behandling af diabetes og fremgangsmåder |
| TW200637839A (en) * | 2005-01-07 | 2006-11-01 | Taisho Pharmaceutical Co Ltd | 1-thio-d-glucitol derivatives |
| KR20090023570A (ko) * | 2006-06-29 | 2009-03-05 | 다이쇼 세이야꾸 가부시끼가이샤 | Ｃ-페닐 1-티오글루시톨 화합물 |
| JP5194588B2 (ja) * | 2006-07-06 | 2013-05-08 | 大正製薬株式会社 | １−チオ−ｄ−グルシトール誘導体を有効成分として含有する糖尿病の予防又は治療剤 |
| CA2656847A1 (en) * | 2006-08-15 | 2008-02-21 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture |
| CL2007003227A1 (es) * | 2006-11-09 | 2008-07-04 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo en combinacion con uno o mas agentes terapeuticos; y uso para el tratamiento de diabetes mellitus, obesidad e hiperglucemia entre otras. |
| EP2103607A4 (en) * | 2006-12-14 | 2011-01-05 | Taisho Pharmaceutical Co Ltd | 1-phenyl-1-thio-D-GLUCITOLDERIVAT |
| PE20090938A1 (es) | 2007-08-16 | 2009-08-08 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo |
| CL2008002425A1 (es) | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composición farmacéutica que comprende un inhibidor de sglt2 y 1-(4-metil-quinazolin-2-il)metil-3metil-7-(-2-butin-1-il)-8-(3-(r)-amino-piperidin-1il)-xantina, un inhibidor de dpp iv y su uso para el tratamiento de la obesidad y de la diabetes tipo 1 y 2 y complicaciones de esta. |
-
2010
- 2010-04-16 AR ARP100101273A patent/AR076317A1/es unknown
- 2010-04-16 SG SG2014012405A patent/SG2014012405A/en unknown
- 2010-04-16 RU RU2011146335/15A patent/RU2532330C2/ru not_active IP Right Cessation
- 2010-04-16 HR HRP20131120AT patent/HRP20131120T1/hr unknown
- 2010-04-16 DK DK10764570.7T patent/DK2419097T3/da active
- 2010-04-16 DK DK13157571.4T patent/DK2601949T3/da active
- 2010-04-16 UA UAA201113444A patent/UA105216C2/ru unknown
- 2010-04-16 US US13/264,687 patent/US20120040898A1/en not_active Abandoned
- 2010-04-16 SG SG2014012553A patent/SG2014012553A/en unknown
- 2010-04-16 SG SG2014014807A patent/SG2014014807A/en unknown
- 2010-04-16 MX MX2011010901A patent/MX2011010901A/es active IP Right Grant
- 2010-04-16 SI SI201030365T patent/SI2419097T1/sl unknown
- 2010-04-16 UA UAA201314870A patent/UA111742C2/uk unknown
- 2010-04-16 NZ NZ606888A patent/NZ606888A/en not_active IP Right Cessation
- 2010-04-16 PL PL13157571T patent/PL2601949T3/pl unknown
- 2010-04-16 AU AU2010237748A patent/AU2010237748B2/en not_active Ceased
- 2010-04-16 PT PT107645707T patent/PT2419097E/pt unknown
- 2010-04-16 MY MYPI2015001281A patent/MY183793A/en unknown
- 2010-04-16 NZ NZ595314A patent/NZ595314A/xx unknown
- 2010-04-16 SI SI201030784T patent/SI2601949T1/sl unknown
- 2010-04-16 KR KR1020157009538A patent/KR20150046382A/ko not_active Ceased
- 2010-04-16 EP EP10764570.7A patent/EP2419097B1/en active Active
- 2010-04-16 WO PCT/JP2010/057196 patent/WO2010119990A1/en not_active Ceased
- 2010-04-16 RS RS20150042A patent/RS53761B1/sr unknown
- 2010-04-16 PL PL10764570T patent/PL2419097T3/pl unknown
- 2010-04-16 ES ES13157571.4T patent/ES2523408T3/es active Active
- 2010-04-16 BR BRPI1012539A patent/BRPI1012539A2/pt not_active IP Right Cessation
- 2010-04-16 CA CA2755392A patent/CA2755392A1/en not_active Abandoned
- 2010-04-16 ME MEP-2015-6A patent/ME02015B/me unknown
- 2010-04-16 SG SG2014015093A patent/SG2014015093A/en unknown
- 2010-04-16 MY MYPI2011004937A patent/MY156679A/en unknown
- 2010-04-16 CN CN201510876712.4A patent/CN105343871A/zh active Pending
- 2010-04-16 SG SG2014012462A patent/SG2014012462A/en unknown
- 2010-04-16 EP EP13157571.4A patent/EP2601949B1/en active Active
- 2010-04-16 EP EP14183168.5A patent/EP2829271A3/en not_active Withdrawn
- 2010-04-16 SG SG2011073848A patent/SG175154A1/en unknown
- 2010-04-16 TW TW105105937A patent/TW201622720A/zh unknown
- 2010-04-16 TW TW099111992A patent/TW201103534A/zh unknown
- 2010-04-16 ME MEP-2013-137A patent/ME01555B/me unknown
- 2010-04-16 NZ NZ710575A patent/NZ710575A/en not_active IP Right Cessation
- 2010-04-16 RS RS20130508A patent/RS53056B/sr unknown
- 2010-04-16 CN CN201510876753.3A patent/CN105434430A/zh active Pending
- 2010-04-16 KR KR1020117023612A patent/KR20120016051A/ko not_active Ceased
- 2010-04-16 CN CN201510876636.7A patent/CN105343059A/zh active Pending
- 2010-04-16 ES ES10764570T patent/ES2431300T3/es active Active
- 2010-04-16 MY MYPI2015001283A patent/MY182720A/en unknown
- 2010-04-16 JP JP2011540651A patent/JP5077786B2/ja active Active
- 2010-04-16 PT PT131575714T patent/PT2601949E/pt unknown
- 2010-04-16 CN CN2010800169522A patent/CN102395364A/zh active Pending
- 2010-04-16 CN CN201510876708.8A patent/CN105343060A/zh active Pending
- 2010-04-16 CN CN201510876678.0A patent/CN105477639A/zh active Pending
- 2010-04-16 NZ NZ623838A patent/NZ623838A/en not_active IP Right Cessation
- 2010-04-16 CN CN201510876739.3A patent/CN105343880A/zh active Pending
- 2010-04-16 TW TW103133246A patent/TW201500043A/zh unknown
-
2011
- 2011-09-14 ZA ZA2011/06727A patent/ZA201106727B/en unknown
-
2012
- 2012-08-31 JP JP2012191753A patent/JP5660094B2/ja not_active Expired - Fee Related
-
2013
- 2013-12-05 CY CY20131101103T patent/CY1114703T1/el unknown
-
2014
- 2014-05-26 RU RU2014121260/15A patent/RU2014121260A/ru not_active Application Discontinuation
- 2014-11-05 HR HRP20141080AT patent/HRP20141080T1/hr unknown
- 2014-12-03 JP JP2014245257A patent/JP5910711B2/ja active Active
-
2015
- 2015-01-16 CY CY20151100045T patent/CY1115907T1/el unknown
- 2015-01-19 SM SM201500015T patent/SMT201500015B/xx unknown
- 2015-02-03 PH PH12015500235A patent/PH12015500235A1/en unknown
- 2015-12-25 JP JP2015253932A patent/JP6066144B2/ja active Active
-
2016
- 2016-05-11 HK HK16105353.2A patent/HK1217302A1/zh unknown
- 2016-05-11 HK HK16105348.0A patent/HK1217301A1/zh unknown
- 2016-05-12 HK HK16105417.6A patent/HK1217435A1/zh unknown
- 2016-05-12 HK HK16105415.8A patent/HK1217434A1/zh unknown
- 2016-06-16 HK HK16106920.4A patent/HK1218871A1/zh unknown
- 2016-06-17 HK HK16106970.3A patent/HK1218881A1/zh unknown
-
2019
- 2019-04-30 PH PH12019500961A patent/PH12019500961A1/en unknown
- 2019-04-30 PH PH12019500959A patent/PH12019500959B1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20141080T1 (hr) | Farmaceutski pripravci s (1s) -1,5-anhidro-1 [5-(4-etoksibenzil)-2-metoksi-4-metilfenil]-1-tio-d-glucitolom i sekretagogom inzulina | |
| ME02277B (me) | Postupak za prečišćavanje rekombinantnog fsh | |
| HRP20151230T1 (hr) | Liksisenatid kao dodatak metforminu kod lijeäśenja dijabetesa tipa 2 | |
| HRP20231586T1 (hr) | Agonisti receptora glukagonu sličnog peptida 1 | |
| JP2014533680A5 (enExample) | ||
| FI3716979T3 (fi) | 4-pyrimidiinisulfamidijohdannaisen ja SGLT-2-inhibiittorin yhdistelmä endoteliiniin liittyvien sairauksien hoitamiseksi | |
| HRP20200828T1 (hr) | Farmaceutski pripravak koji sadrži sglt2-inhibitor, dpp-iv-inhibitor i prema potrebi jedno dodatno antidijabetičko sredstvo, te njegove uporabe | |
| JP2013525444A5 (enExample) | ||
| JP2023541430A5 (enExample) | ||
| JP2010529118A5 (enExample) | ||
| JP2012236849A5 (enExample) | ||
| BRPI0818687A2 (pt) | composto espiro, o sal deste farmaceuticamente aceitavél ou o solvato deste, composição farmacêutica, medicamento agonista de gpr40, agente promotor da secreção de insulina ou um agente hipoglicêmico, uso do composto espíro, o sal deste farmaceuticamente aceitavél ou o solvato deste, e, métodos para a ativação de gpr40, para promover secreção de insulina ou diminuir o nível de glicose sanguínea, e para tratar ou prevenir uma doença. | |
| JP2009500443A5 (enExample) | ||
| JP2019517542A5 (enExample) | ||
| FI3504187T3 (fi) | Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten | |
| HRP20230470T1 (hr) | Formulacija fiksnog omjera inzulin glargin/liksisenatid | |
| ME01546B (me) | Liksisenatid kao dodatna terapija insulin glarginu i metforminu za liječenje dijabetesa tipa 2 | |
| BR112013032122A2 (pt) | liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos | |
| JP2019089796A5 (enExample) | ||
| WO2016060517A3 (ko) | 신규한 3-(4- (벤질옥시)페닐)핵스- 4-이노익 산 유도체 및 다른 유효 성분을 포함하는 대사성 질환의 예방 또는 치료용 복합제제 | |
| JP2008545715A5 (enExample) | ||
| JP2015518007A5 (enExample) | ||
| JP2014513121A5 (enExample) | ||
| WO2009133470A3 (en) | Use of dronedarone alone or in combination for preparing a medicament for the treatment of patients with arrhythmia and having an increase of creatinine level | |
| JP2006517557A5 (enExample) |